|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
EP3307876B1
(en)
|
2015-06-10 |
2023-09-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
AU2016306209B2
(en)
|
2015-08-07 |
2023-07-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific CAR T-cells for solid tumor targeting
|
|
CA3025667A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
CA3048907C
(en)
*
|
2017-01-06 |
2023-05-23 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
|
EP3568474A1
(en)
*
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
WO2018144777A2
(en)
*
|
2017-02-01 |
2018-08-09 |
Nant Holdings Ip, Llc |
Calreticulin-mediated cancer treatment
|
|
SG11201907638QA
(en)
*
|
2017-02-20 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding cd33, nkg2d and cd16
|
|
US10801013B2
(en)
*
|
2017-03-08 |
2020-10-13 |
Nantkwest, Inc. |
Modified NK-92 haNK003 cells for the clinic
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
KR20190126182A
(ko)
*
|
2017-03-27 |
2019-11-08 |
난트셀, 인크. |
aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS)
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
KR102009040B1
(ko)
*
|
2017-04-05 |
2019-08-08 |
한국생명공학연구원 |
Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물
|
|
WO2018191619A1
(en)
*
|
2017-04-13 |
2018-10-18 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
TWI676483B
(zh)
*
|
2017-08-06 |
2019-11-11 |
強普生技股份有限公司 |
醫藥套組及其用途
|
|
US11771718B2
(en)
*
|
2017-10-18 |
2023-10-03 |
Precigen, Inc. |
Polypeptide compositions comprising spacers
|
|
US12053490B2
(en)
|
2017-10-26 |
2024-08-06 |
St. Jude Children's Research Hospital, Inc. |
Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
|
|
WO2019089813A1
(en)
*
|
2017-11-01 |
2019-05-09 |
Nantkwest, Inc. |
Nk-92 cells to stimulate anti-cancer vaccine
|
|
WO2019101998A1
(en)
|
2017-11-24 |
2019-05-31 |
Onkimmune Limited |
Modified natural killer cells and natural killer cell lines targetting tumour cells
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
CN110028589B
(zh)
*
|
2018-02-07 |
2023-07-21 |
阿思科力(苏州)生物科技有限公司 |
嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
CA3091224A1
(en)
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
WO2019182422A1
(ko)
*
|
2018-03-23 |
2019-09-26 |
주식회사 에스엘바이젠 |
신규 유전자 변형 자연살해 세포주 및 그의 용도
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
IL321548A
(en)
*
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
JP7241161B2
(ja)
*
|
2018-08-01 |
2023-03-16 |
イミュニティーバイオ、インコーポレイテッド |
細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
|
|
WO2020028654A1
(en)
|
2018-08-01 |
2020-02-06 |
Nantkwest, Inc. |
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
EP3743512A4
(en)
*
|
2018-10-31 |
2021-12-01 |
Nantkwest, Inc. |
ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS
|
|
KR102533540B1
(ko)
*
|
2018-10-31 |
2023-05-17 |
난트퀘스트, 인크. |
Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
|
|
US12109238B2
(en)
|
2018-11-06 |
2024-10-08 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
IL277414B2
(en)
*
|
2018-11-06 |
2025-04-01 |
Immunitybio Inc |
NK–92 cells with chimeric antigen receptor modification
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
CN113164521A
(zh)
*
|
2018-11-26 |
2021-07-23 |
免疫生物公司 |
具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
EP3938495A4
(en)
|
2019-03-15 |
2023-04-26 |
Nantcell, Inc. |
RECOMBINANT ERIL-15 NK CELLS
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
CA3148608A1
(en)
*
|
2019-07-26 |
2021-02-04 |
Immunitybio, Inc. |
Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
|
|
IL283568B2
(en)
*
|
2019-08-01 |
2025-01-01 |
Immunitybio Inc |
NK–92 cells modified with a chimeric antigen receptor against B7–H4
|
|
EP4032972A4
(en)
*
|
2019-09-18 |
2024-07-24 |
Slbigen Inc. |
GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NEW CHIMERIC ANTIGEN RECEPTOR AND ITS USE
|
|
US20210106619A1
(en)
*
|
2019-10-10 |
2021-04-15 |
Nantkwest, Inc. |
NK-92 Bone and Brain targeting
|
|
WO2021101467A1
(en)
*
|
2019-11-19 |
2021-05-27 |
Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ |
A method for redesign and expansion of nk92 cells for use in immunotherapy
|
|
AU2020387167B2
(en)
*
|
2019-11-20 |
2024-10-24 |
Immunitybio, Inc. |
Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
|
|
CN113646435A
(zh)
|
2019-12-09 |
2021-11-12 |
南克维斯特公司 |
通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
|
|
CN115315510A
(zh)
*
|
2020-01-28 |
2022-11-08 |
免疫生物公司 |
靶向egfr超家族受体的嵌合抗原受体修饰的nk-92细胞
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
EP4097220A4
(en)
*
|
2020-01-30 |
2024-03-20 |
ImmunityBio, Inc. |
ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
CA3176258A1
(en)
*
|
2020-03-28 |
2021-10-07 |
Board Of Regents, The University Of Texas System |
Cell immunotherapy for the treatment of cancer
|
|
KR20230152783A
(ko)
|
2020-07-07 |
2023-11-03 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
|
MX2023004811A
(es)
*
|
2020-10-26 |
2023-06-29 |
Res Institute At Nationwide Children´S Hospital |
Células nk del receptor de antígeno quimérico (car) y usos de las mismas.
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
WO2024236557A1
(en)
|
2023-05-12 |
2024-11-21 |
Gilboa Therapeutics LTD |
Compositions comprising an fc domain for the treatment of medical conditions
|
|
WO2025158400A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Yale University |
Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
|